

Antonio Daniele

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7966866/publications.pdf>

Version: 2024-02-01

48
papers

4,778
citations

218677

26
h-index

206112

48
g-index

50
all docs

50
docs citations

50
times ranked

8613
citing authors

#	ARTICLE	IF	CITATIONS
1	Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates A β , tau, immunity and lipid processing. <i>Nature Genetics</i> , 2019, 51, 414-430.	21.4	1,962
2	Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. <i>Nature Genetics</i> , 2017, 49, 1373-1384.	21.4	783
3	Relationships of Dietary Patterns, Foods, and Micro- and Macronutrients with Alzheimer's Disease and Late-Life Cognitive Disorders: A Systematic Review. <i>Journal of Alzheimer's Disease</i> , 2017, 59, 815-849.	2.6	249
4	Different Cognitive Frailty Models and Health- and Cognitive-related Outcomes in Older Age: From Epidemiology to Prevention. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 993-1012.	2.6	214
5	Tau-Centric Targets and Drugs in Clinical Development for the Treatment of Alzheimer's Disease. <i>BioMed Research International</i> , 2016, 2016, 1-15.	1.9	138
6	Reversible Cognitive Frailty, Dementia, and All-Cause Mortality. The Italian Longitudinal Study on Aging. <i>Journal of the American Medical Directors Association</i> , 2017, 18, 89.e1-89.e8.	2.5	126
7	Additive Role of a Potentially Reversible Cognitive Frailty Model and Inflammatory State on the Risk of Disability: The Italian Longitudinal Study on Aging. <i>American Journal of Geriatric Psychiatry</i> , 2017, 25, 1236-1248.	1.2	90
8	Development of disease-modifying drugs for frontotemporal dementia spectrum disorders. <i>Nature Reviews Neurology</i> , 2020, 16, 213-228.	10.1	73
9	Sensorial frailty: age-related hearing loss and the risk of cognitive impairment and dementia in later life. <i>Therapeutic Advances in Chronic Disease</i> , 2019, 10, 204062231881100.	2.5	68
10	BACE inhibitors in clinical development for the treatment of Alzheimer's disease. <i>Expert Review of Neurotherapeutics</i> , 2018, 18, 847-857.	2.8	66
11	Tau-based therapeutics for Alzheimer's disease: active and passive immunotherapy. <i>Immunotherapy</i> , 2016, 8, 1119-1134.	2.0	61
12	Anti-amyloid- β protein agents for the treatment of Alzheimer's disease: an update on emerging drugs. <i>Expert Opinion on Emerging Drugs</i> , 2020, 25, 319-335.	2.4	57
13	Emerging drugs to reduce abnormal β -amyloid protein in Alzheimer's disease patients. <i>Expert Opinion on Emerging Drugs</i> , 2016, 21, 377-391.	2.4	54
14	Suicidal behaviour in older age: A systematic review of risk factors associated to suicide attempts and completed suicides. <i>Neuroscience and Biobehavioral Reviews</i> , 2021, 127, 193-211.	6.1	54
15	Physical Frailty, Multimorbidity, and All-Cause Mortality in an Older Population From Southern Italy: Results from the Salus in Apulia Study. <i>Journal of the American Medical Directors Association</i> , 2021, 22, 598-605.	2.5	53
16	Are antibodies directed against amyloid- β (A β) oligomers the last call for the A β hypothesis of Alzheimer's disease?. <i>Immunotherapy</i> , 2019, 11, 3-6.	2.0	50
17	Biopsychosocial frailty and the risk of incident dementia: The Italian longitudinal study on aging. <i>Alzheimer's and Dementia</i> , 2019, 15, 1019-1028.	0.8	47
18	Pharmacotherapy for the treatment of depression in patients with Alzheimer's disease: a treatment-resistant depressive disorder. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 823-842.	1.8	43

#	ARTICLE	IF	CITATIONS
19	Cognitive frailty: a potential target for secondary prevention of dementia. Expert Opinion on Drug Metabolism and Toxicology, 2017, 13, 1023-1027.	3.3	40
20	Nutritional Intervention as a Preventive Approach for Cognitive-Related Outcomes in Cognitively Healthy Older Adults: A Systematic Review. Journal of Alzheimer's Disease, 2018, 64, S229-S254.	2.6	38
21	Botulinum Toxin Type A for the Treatment of Lower Limb Spasticity after Stroke. Drugs, 2019, 79, 143-160.	10.9	38
22	Innovative biomarkers in psychiatric disorders: a major clinical challenge in psychiatry. Expert Review of Proteomics, 2017, 14, 809-824.	3.0	36
23	Tau-directed approaches for the treatment of Alzheimer's disease: focus on leuco-methylthioninium. Expert Review of Neurotherapeutics, 2016, 16, 259-277.	2.8	35
24	The potential of solanezumab and gantenerumab to prevent Alzheimer's disease in people with inherited mutations that cause its early onset. Expert Opinion on Biological Therapy, 2018, 18, 25-35.	3.1	34
25	Oral frailty and neurodegeneration in Alzheimer's disease. Neural Regeneration Research, 2021, 16, 2149.	3.0	34
26	The Role of Biomarkers in Psychiatry. Advances in Experimental Medicine and Biology, 2019, 1118, 135-162.	1.6	29
27	Nutritional interventions and cognitive-related outcomes in patients with late-life cognitive disorders: A systematic review. Neuroscience and Biobehavioral Reviews, 2018, 95, 480-498.	6.1	27
28	An Old Challenge with New Promises: A Systematic Review on Comprehensive Geriatric Assessment in Long-Term Care Facilities. Rejuvenation Research, 2018, 21, 3-14.	1.8	25
29	Freezing of gait in Parkinson's disease: The paradoxical interplay between gait and cognition. Parkinsonism and Related Disorders, 2014, 20, 824-829.	2.2	24
30	Social Frailty in the COVID-19 Pandemic Era. Frontiers in Psychiatry, 2020, 11, 577113.	2.6	20
31	Role of CLU, PICALM, and TNK1 Genotypes in Aging With and Without Alzheimer's Disease. Molecular Neurobiology, 2018, 55, 4333-4344.	4.0	19
32	Executive Dysfunction Detected with the Frontal Assessment Battery in Alzheimer's Disease Versus Vascular Dementia. Journal of Alzheimer's Disease, 2018, 62, 699-711.	2.6	17
33	Promising therapies for the treatment of frontotemporal dementia clinical phenotypes: from symptomatic to disease-modifying drugs. Expert Opinion on Pharmacotherapy, 2019, 20, 1091-1107.	1.8	15
34	Disease-modifying therapies for tauopathies: agents in the pipeline. Expert Review of Neurotherapeutics, 2019, 19, 397-408.	2.8	15
35	Pharmacogenetics of neurological and psychiatric diseases at older age: has the time come?. Expert Opinion on Drug Metabolism and Toxicology, 2017, 13, 259-277.	3.3	13
36	The relationship between epigenetics and microbiota in neuropsychiatric diseases. Epigenomics, 2020, 12, 1559-1568.	2.1	11

#	ARTICLE	IF	CITATIONS
37	Psychiatry meets pharmacogenetics for the treatment of revolving door patients with psychiatric disorders. <i>Expert Review of Neurotherapeutics</i> , 2016, 16, 1357-1369.	2.8	10
38	High doses of incobotulinumtoxinA for the treatment of post-stroke spasticity: are they safe and effective?. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016, 12, 843-846.	3.3	10
39	Vitamin D in the development and progression of alzheimerâ€™s disease: implications for clinical management. <i>Expert Review of Neurotherapeutics</i> , 2021, 21, 287-301.	2.8	9
40	Psychotropic drugs and CYP2D6 in late-life psychiatric and neurological disorders. What do we know?. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 1373-1385.	2.4	8
41	The pharmacogenetic road to avoid adverse drug reactions and therapeutic failures in revolving door patients with psychiatric illnesses: focus on the CYP2D6 isoenzymes. <i>Expert Review of Precision Medicine and Drug Development</i> , 2016, 1, 431-442.	0.7	6
42	Frailty and outcome after traumatic brain injury. <i>Lancet Neurology</i> , The, 2022, 21, 107-108.	10.2	6
43	ALZT-OP1: an experimental combination regimen for the treatment of Alzheimerâ€™s disease. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 759-771.	4.1	6
44	Processed meat consumption and the risk of incident late-onset depression: a 12-year follow-up of the Salus in Apulia Study. <i>Age and Ageing</i> , 2022, 51, .	1.6	5
45	Can pharmacotherapy effectively reduce Alzheimerâ€™s related agitation?. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 1517-1522.	1.8	4
46	The Challenge of Antidepressant Therapeutics in Alzheimerâ€™s Disease. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1260, 267-281.	1.6	4
47	The diagnostic accuracy of late-life depression is influenced by subjective memory complaints and educational level in an older population in Southern Italy. <i>Psychiatry Research</i> , 2022, 308, 114346.	3.3	3
48	Pharmacogenetics in the clinical analysis laboratory: clinical practice, research, and drug development pipeline. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2019, 15, 751-765.	3.3	0